The 3CLpro (SARS-CoV-2) assay kit (BPS Bioscience, San Diego CA, cat. no. 78042-2) is designed to measure 3CLpro activity and identify inhibitors of this enzyme, while human cathepsin L inhibitor screening kit (abcam, cat. Cambridge, UK, No. ab197012) and human calpain activity assay kit (AnaSpec. Inc. Fremont CA, cat. No. AS-72149) are designed to measure human cysteine protease activity and identify inhibitors of these enzymes. These assays were performed in a 96-well plate using a fluorogenic substrate. Briefly, a solution of each enzyme was prepared according to the manufacturer’s protocol in assay buffer. Separately, solutions of test compounds necessary to generate a seven-point dose response curve were prepared in half-log serial dilution. Test compounds were added to the plate, and the mixture was preincubated for 30 min at room temperature. A blank well (no enzyme) was included to assess the background signal, while the known inhibitors GC376, FF-FMK and B27-WT were used as positive controls for SARS-CoV-2 Mpro/3CLpro, cathepsin L, and calpain, respectively. The plates of SARS-CoV-2 Mpro, cathepsin L, and calpain were incubated with each fluorogenic substrate for 4, 0.3, and 1 h, respectively, at room temperature. Then fluorescence intensity was measured in a Cytation 5 cell imaging multi-mode reader (BioTek, Winooski, VT, USA)(excitation/emission: 360/460 nm, excitation/emission: 400/505 nm, and excitation/emission: 490/520 nm), respectively. End point fluorescence intensities were measured, and the blank value were subtracted from all values.
Higashi-Kuwata N., Tsuji K., Hayashi H., Bulut H., Kiso M., Imai M., Ogata-Aoki H., Ishii T., Kobayakawa T., Nakano K., Takamune N., Kishimoto N., Hattori S.I., Das D., Uemura Y., Shimizu Y., Aoki M., Hasegawa K., Suzuki S., Nishiyama A., Saruwatari J., Shimizu Y., Sukenaga Y., Takamatsu Y., Tsuchiya K., Maeda K., Yoshimura K., Iida S., Ozono S., Suzuki T., Okamura T., Misumi S., Kawaoka Y., Tamamura H, & Mitsuya H. (2023). Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature Communications, 14, 1076.